Eledon Pharmaceuticals Has Enrolled The 80th Participant In Its Ongoing Phase 2 BESTOW Trial Of Tegoprubart To Prevent Rejection In Kidney Transplantation, The Company Remains On Track To Complete Enrollment By The End Of The Year
Portfolio Pulse from Benzinga Newsdesk
Eledon Pharmaceuticals has enrolled the 80th participant in its Phase 2 BESTOW trial of Tegoprubart, aimed at preventing rejection in kidney transplantation. The company is on track to complete enrollment by the end of the year.

July 29, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eledon Pharmaceuticals has reached a significant milestone by enrolling the 80th participant in its Phase 2 BESTOW trial for Tegoprubart, which aims to prevent kidney transplant rejection. The company is on track to complete enrollment by the end of the year.
The enrollment of the 80th participant in the Phase 2 BESTOW trial is a significant milestone for Eledon Pharmaceuticals. This progress indicates that the company is on track with its clinical development timeline, which is positive news for investors. The completion of enrollment by the end of the year could lead to further advancements and potential positive outcomes in the trial, likely boosting investor confidence and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100